95 related articles for article (PubMed ID: 2078410)
21. The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160.
Fenouillet E; Jones IM
J Gen Virol; 1995 Jun; 76 ( Pt 6)():1509-14. PubMed ID: 7782780
[TBL] [Abstract][Full Text] [Related]
22. Identification and characterization of fusion and processing domains of the human immunodeficiency virus type 2 envelope glycoprotein.
Freed EO; Myers DJ
J Virol; 1992 Sep; 66(9):5472-8. PubMed ID: 1501283
[TBL] [Abstract][Full Text] [Related]
23. Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation.
Owens BJ; Anantharamaiah GM; Kahlon JB; Srinivas RV; Compans RW; Segrest JP
J Clin Invest; 1990 Oct; 86(4):1142-50. PubMed ID: 2170446
[TBL] [Abstract][Full Text] [Related]
24. Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein.
Baldwin CE; Berkhout B
Retrovirology; 2006 Nov; 3():84. PubMed ID: 17134507
[TBL] [Abstract][Full Text] [Related]
25. Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function.
Chiou SH; Freed EO; Panganiban AT; Kenealy WR
AIDS Res Hum Retroviruses; 1992 Sep; 8(9):1611-8. PubMed ID: 1457207
[TBL] [Abstract][Full Text] [Related]
26. Effects of cytoplasmic domain length on cell surface expression and syncytium-forming capacity of the simian immunodeficiency virus envelope glycoprotein.
Spies CP; Compans RW
Virology; 1994 Aug; 203(1):8-19. PubMed ID: 8030287
[TBL] [Abstract][Full Text] [Related]
27. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
Jiang S; Debnath AK
Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
[TBL] [Abstract][Full Text] [Related]
28. Calmodulin antagonists inhibit human immunodeficiency virus-induced cell fusion but not virus replication.
Srinivas RV; Bernstein H; Oliver C; Compans RW
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1489-96. PubMed ID: 7888203
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of fusion peptide homologs in blocking cell lysis and HIV-induced fusion.
Silburn KA; McPhee DA; Maerz AL; Poumbourios P; Whittaker RG; Kirkpatrick A; Reilly WG; Manthey MK; Curtain CC
AIDS Res Hum Retroviruses; 1998 Mar; 14(5):385-92. PubMed ID: 9546797
[TBL] [Abstract][Full Text] [Related]
30. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.
Fenouillet E; Miquelis R; Drillien R
Virology; 1996 Apr; 218(1):224-31. PubMed ID: 8615025
[TBL] [Abstract][Full Text] [Related]
31. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.
Pritsker M; Rucker J; Hoffman TL; Doms RW; Shai Y
Biochemistry; 1999 Aug; 38(35):11359-71. PubMed ID: 10471286
[TBL] [Abstract][Full Text] [Related]
32. The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation.
Huang JH; Yang HW; Liu S; Li J; Jiang S; Chen YH
Biochem J; 2007 May; 403(3):565-71. PubMed ID: 17223796
[TBL] [Abstract][Full Text] [Related]
33. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
Verrier F; Borman AM; Brand D; Girard M
AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
[TBL] [Abstract][Full Text] [Related]
34. Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues.
Delahunty MD; Rhee I; Freed EO; Bonifacino JS
Virology; 1996 Apr; 218(1):94-102. PubMed ID: 8615045
[TBL] [Abstract][Full Text] [Related]
35. Contagious apoptosis facilitated by the HIV-1 envelope: fusion-induced cell-to-cell transmission of a lethal signal.
Andreau K; Perfettini JL; Castedo M; Métivier D; Scott V; Pierron G; Kroemer G
J Cell Sci; 2004 Nov; 117(Pt 23):5643-53. PubMed ID: 15494371
[TBL] [Abstract][Full Text] [Related]
36. Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41.
Gallo SA; Clore GM; Louis JM; Bewley CA; Blumenthal R
Biochemistry; 2004 Jun; 43(25):8230-3. PubMed ID: 15209519
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of human immunodeficiency virus type 1 (HIV-1) penetration into target cells by synthetic peptides mimicking the N-terminus of the HIV-1 transmembrane glycoprotein.
Slepushkin VA; Kornilaeva GV; Andreev SM; Sidorova MV; Petrukhina AO; Matsevich GR; Raduk SV; Grigoriev VB; Makarova TV; Lukashov VV
Virology; 1993 May; 194(1):294-301. PubMed ID: 7683157
[TBL] [Abstract][Full Text] [Related]
38. Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation.
Andeweg AC; Leeflang P; Osterhaus AD; Bosch ML
J Virol; 1993 Jun; 67(6):3232-9. PubMed ID: 7684463
[TBL] [Abstract][Full Text] [Related]
39. A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity.
Freed EO; Delwart EL; Buchschacher GL; Panganiban AT
Proc Natl Acad Sci U S A; 1992 Jan; 89(1):70-4. PubMed ID: 1729720
[TBL] [Abstract][Full Text] [Related]
40. Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion.
Schaal H; Klein M; Gehrmann P; Adams O; Scheid A
J Virol; 1995 Jun; 69(6):3308-14. PubMed ID: 7745678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
